{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:10:34Z","timestamp":1778515834046,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["19\/213"],"award-info":[{"award-number":["19\/213"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["F.19F"],"award-info":[{"award-number":["F.19F"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001513","name":"Cancer Society of New Zealand Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","award":["1117020"],"award-info":[{"award-number":["1117020"]}],"id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.radonc.2021.11.027","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:38:43Z","timestamp":1638293923000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648"],"prefix":"10.1016","volume":"166","author":[{"given":"Cho R.","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal D.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Way W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praju V.","family":"Anekal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin D.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gib","family":"Bogle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin O.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.11.027_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.dnarep.2014.02.020","article-title":"DNA-PK: A dynamic enzyme in a versatile DSB repair pathway","volume":"17","author":"Davis","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.radonc.2021.11.027_b0010","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1074\/jbc.TM117.000374","article-title":"Nonhomologous DNA end-joining for repair of DNA double-strand breaks","volume":"293","author":"Pannunzio","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.radonc.2021.11.027_b0015","first-page":"111692","article-title":"Targeting DNA-PK in cancer","volume":"821","author":"Damia","year":"2020","journal-title":"Mutat Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/347479a0","article-title":"The scid mutation in mice causes a general defect in DNA repair","volume":"347","author":"Fulop","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2021.11.027_b0025","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1073\/pnas.88.4.1394","article-title":"Scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair","volume":"88","author":"Biedermann","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2021.11.027_b0030","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1126\/science.7855601","article-title":"DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect","volume":"267","author":"Kirchgessner","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.radonc.2021.11.027_b0035","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/nar\/28.7.1506","article-title":"The C-terminal conserved domain of DNA-PKcs, missing in the SCID mouse, is required for kinase activity","volume":"28","author":"Beamish","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0040","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1172\/JCI67349","article-title":"PRKDC mutations in a SCID patient with profound neurological abnormalities","volume":"123","author":"Woodbine","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.radonc.2021.11.027_b0045","doi-asserted-by":"crossref","first-page":"113641","DOI":"10.1016\/j.bcp.2019.113641","article-title":"Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361","volume":"169","author":"Wong","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.radonc.2021.11.027_b0050","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1073\/pnas.94.15.8076","article-title":"Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination","volume":"94","author":"Gu","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2021.11.027_b0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.7939667","article-title":"Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA","volume":"266","author":"Smider","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.radonc.2021.11.027_b0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cmdc.201700143","article-title":"Targeting DNA-dependent protein kinase for cancer therapy","volume":"12","author":"Harnor","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.radonc.2021.11.027_b0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13543776.2021.1866540","article-title":"Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present)","volume":"31","author":"Hu","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.radonc.2021.11.027_b0070","first-page":"6008","article-title":"Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1","volume":"63","author":"Veuger","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0075","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1158\/0008-5472.CAN-04-4250","article-title":"DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs","volume":"65","author":"Shinohara","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0080","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/09553002.2019.1664787","article-title":"Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia","volume":"95","author":"Lee","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2021.11.027_b0085","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.radonc.2021.11.027_b0090","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.radonc.2021.11.027_b0095","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2021.11.027_b0100","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41416-020-01151-6","article-title":"A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours","volume":"124","author":"van Bussel","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2021.11.027_b0105","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/acs.jmedchem.9b01684","article-title":"The discovery of 7-methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2h-p yran-4-yl)-7,9-dihydro-8h-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor","volume":"63","author":"Goldberg","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2021.11.027_b0110","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","article-title":"Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control","volume":"27","author":"Nakamura","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.dnarep.2006.05.022","article-title":"Differential usage of non-homologous end-joining and homologous recombination in double strand break repair","volume":"5","author":"Sonoda","year":"2006","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.radonc.2021.11.027_b0120","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.ijrobp.2018.11.063","article-title":"Beware of clinical trials of DNA repair inhibitors","volume":"103","author":"Brown","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.11.027_b0125","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0130","unstructured":"Ebert A von Neubeck C, Naas P, Schulz A, Lock A, Zimmermann A, Krause M, Baumann M. Therapeutic effects of combined radiotherapy and DNA dependent protein kinase inhibitor. Abstract PS02. 64th Annual Meeting Radiation Research Society, Chicago, Illinois, USA Sept 2018."},{"key":"10.1016\/j.radonc.2021.11.027_b0135","doi-asserted-by":"crossref","first-page":"viii654","DOI":"10.1093\/annonc\/mdy303.015","article-title":"Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: results from two phase I trials","volume":"29","author":"Mau-Sorensen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.11.027_b0140","doi-asserted-by":"crossref","unstructured":"Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A et al. Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. J Clin Invest 2020;130:258-271.","DOI":"10.1172\/JCI127483"},{"key":"10.1016\/j.radonc.2021.11.027_b0145","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2021.11.027_b0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09553007014550291","article-title":"Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation","volume":"17","author":"Withers","year":"1970","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"10.1016\/j.radonc.2021.11.027_b0155","doi-asserted-by":"crossref","first-page":"e122204","DOI":"10.1172\/jci.insight.122204","article-title":"Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma","volume":"3","author":"Jamieson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.radonc.2021.11.027_b0160","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0022-3565(24)29637-3","article-title":"Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells","volume":"297","author":"Hicks","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.radonc.2021.11.027_b0165","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0360-3016(98)00268-5","article-title":"Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model","volume":"42","author":"Hicks","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.11.027_b0170","doi-asserted-by":"crossref","first-page":"e1006469","DOI":"10.1371\/journal.pcbi.1006469","article-title":"An agent-based model for drug-radiation interactions in the tumour microenvironment: hypoxia-activated prodrug SN30000 in multicellular tumour spheroids","volume":"14","author":"Mao","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.radonc.2021.11.027_b0175","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13014-017-0939-0","article-title":"Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation","volume":"12","author":"Klein","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.11.027_b0180","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1535-7163.MCT-20-0857","article-title":"DNAPK inhibition preferentially compromises the repair of radiation-induced DNA double-strand breaks in chronically hypoxic tumor cells in xenograft models","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.radonc.2021.11.027_b0185","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0190","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/sj.onc.1210001","article-title":"Repression of RAD51 gene expression by E2F4\/p130 complexes in hypoxia","volume":"26","author":"Bindra","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2021.11.027_b0195","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-07-5472","article-title":"Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance","volume":"68","author":"Chan","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0200","doi-asserted-by":"crossref","unstructured":"Bodo S, Campagne C, Thin TH, Higginson DS, Vargas HA, Hua G et al. Single-dose radiotherapy disables tumor cell homologous recombination via ischemia\/reperfusion injury. J Clin Invest 2019;129:786-801.","DOI":"10.1172\/JCI97631"},{"key":"10.1016\/j.radonc.2021.11.027_b0205","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/0008-5472.CAN-09-1562","article-title":"Regulation of ceramide synthase-mediated crypt epithelium apoptosis by DNA damage repair enzymes","volume":"70","author":"Rotolo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.stem.2011.02.020","article-title":"The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse","volume":"8","author":"Merlos-Su\u00e1rez","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.radonc.2021.11.027_b0215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.stem.2013.11.008","article-title":"Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration","volume":"14","author":"Metcalfe","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.radonc.2021.11.027_b0220","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/0008-5472.CAN-15-2870","article-title":"Distinct levels of radioresistance in Lgr5+ colonic epithelial stem cells versus Lgr5+ small intestinal stem cells","volume":"77","author":"Hua","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0225","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/09553007514550411","article-title":"Differential regeneration of intestinal proliferative cells and cryptogenic cells after irradiation","volume":"27","author":"Potten","year":"1975","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"10.1016\/j.radonc.2021.11.027_b0230","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.mrrev.2016.07.007","article-title":"Tissue reactions to ionizing radiation - oral mucosa","volume":"770","author":"Gruber","year":"2016","journal-title":"Mutat Res"},{"key":"10.1016\/j.radonc.2021.11.027_b0235","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2478\/tumor-2013-0003","article-title":"Selective radiosensitization of hypoxic cells using BCCA621c: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase","volume":"1","author":"Lindquist","year":"2013","journal-title":"Tumor Microenviron Ther"},{"key":"10.1016\/j.radonc.2021.11.027_b0240","unstructured":"Minchinton AI KA, Evans J, Mann SE, Hynd G. 1,6-naphthridine derivatives as DNA-PK inhibiting compounds and prodrugs. PCT Int Appl. WO 2021050059 A1 20210318 2021."},{"key":"10.1016\/j.radonc.2021.11.027_b0245","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trecan.2018.09.007","article-title":"Synthetically lethal interactions of ATM, ATR, and DNA-PKcs","volume":"4","author":"Kantidze","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.radonc.2021.11.027_b0250","doi-asserted-by":"crossref","first-page":"189ra78","DOI":"10.1126\/scitranslmed.3005814","article-title":"Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors","volume":"5","author":"Riabinska","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.radonc.2021.11.027_b0255","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-20-0502","article-title":"Radiopotentiation profiling of multiple inhibitors of the DNA damage response for early clinical development","volume":"20","author":"Gill","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.radonc.2021.11.027_b0260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fonc.2013.00263","article-title":"The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104","volume":"3","author":"Foehrenbacher","year":"2013","journal-title":"Front Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402109023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402109023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:31:33Z","timestamp":1778513493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402109023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"alternative-id":["S016781402109023X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.11.027","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}